Paolo Tarantino

Dana-Farber Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Stephanie L. Graff

Brown University

UNITED STATES

View details

Eleonora Nicolò

Weill Cornell Medicine

UNITED STATES

View details

Giuseppe Curigliano

European Institute of Oncology

ITALY

View details

Elizabeth Mittendorf

Harvard University

UNITED STATES

View details

Stefania Morganti

University of Milan

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paolo Tarantino

Research Interests

Explore related searches

Contact this professor

Articles (29)

Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates

Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer

Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions

Effects of AKT Inhibitors for PIK3CA/AKT1/PTEN-Altered Advanced or Metastatic Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis

Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study

Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA

Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer

Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Detecting and Managing T-DXd–Related Interstitial Lung Disease: The Five “S” Rules

Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance and Reimbursement

HER2-Low Breast Cancer: a New Subtype?

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges

Response to letter entitled: Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”

The HER2-low revolution in breast oncology: steps forward and emerging challenges

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles

Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Emerging Targeted Therapies for Early Breast Cancer

The Dawn of the Antibody–Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors

HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications

Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons

Collaborators (5)

Stephanie L. Graff

Eleonora Nicolò

Giuseppe Curigliano

Elizabeth Mittendorf

Stefania Morganti

Make your next move.